Journal Mobile Options
Table of Contents
Vol. 63, No. 1, 2007
Issue release date: January 2007
Gynecol Obstet Invest 2007;63:22–27

Conjugated Estrogens and Tibolone Modify the Gonadotrophin Glycosylation Pattern in Postmenopausal Women

Hernandez-Valencia M. · Zarate A. · Sandoval A. · Ruiz M. · Timossi C. · Amato D. · Basurto L.
Unit of Endocrine Research, National Medical Center, Instituto Mexicano del Seguro Social, Mexico City, Mexico

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: The purpose of this study was to evaluate the changes in the percentage of glycosylation of FSH and LH when using conjugated estrogens and tibolone as hormonal therapy (HT) in postmenopausal compared with regular menstrual cycles. Design: The study had three groups, with 10 participants in each group. The control group consisted of 10 women with normal menstrual cycles, a second group with 10 postmenopausal patients who received conjugated estrogens (Premarin 0.625 mg), and a third group had 10 patients who received tibolone (Livial 2.5 mg). All patients had hormonal determinations before and 6 months after the use of HT. Concavalin-A was used to separate the different glycosylated species of gonadotrophins, defined as unbound (UB: triantennary and bisecting oligosaccharides), weakly bound (WB: biantennary and truncated oligosaccharides), and firmly bound isoforms (FB: hybrid- and high-mannose-type oligosaccharides) in patients serum. Elusions containing the fractions with the isoforms were concentrated using Centriprep membranes (Amicon, Beverly, Mass., USA) and the different gonadotrophins isoforms were quantified by chemiluminescence using an automated system Immulite. Results: The pattern of distribution of gonadotrophins glycosylation in patients treated with conjugated estrogens and tibolone was similar to that observed in the control group with normal menstrual cycles, although with different glycosylation percentage. When the glycosylation percentages were compared for FSH, in the fraction UB the glycosylation did not have significant differences, but the fraction WB that has isoforms with high amounts of oligosaccharides showed a different percentage of glycosylation, where the recovery percentage was bigger with tibolone use (p < 0.05). The FB fraction had similar hormonal glycosylation with estrogens and tibolone use. When compared, LH glycosylation showed significant differences (p < 0.05) in the fraction UB with a bigger glycosylation degree, and in the fraction FB with a smaller glycosylation percentage, both in the tibolone group compared with conjugated estrogens use. Conclusions: Our results show that there are different percentages of glycosylation of gonadotrophins depending on type of HT (conjugated estrogens vs tibolone), and this could be of utility in young women with ovarian problem since to know the isoform that more favors to cellular activity could help a better therapeutic.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Wilson CA, Leigh AJ, Chapman AJ: Gonadotrophin glycosylation and function [Review]. J Endocrinol 1990;125:3–14.
  2. Whitcroft SIJ, Stevenson JC: Hormone replacement therapy: risks and benefits. Clin Endocrinol 1992;36:15–20.
  3. Hernandez-Valencia M, Mason M, Fonseca ME, Zarate A: Molecular forms variations of LH and FSH during normal ovary cycle. Ginecol Obstet Mex 1996;64:140–145.
  4. Gharib SD, Wierman ME, Shupnik MA, Chin WW: Molecular biology of the pituitary gonadotrophins. Endocrinol Rev 1990;11:177–180.
  5. Wide L, Naessen T: 17β-Oestradiol counteracts the formation of the more acidic isoforms of follicle-stimulating hormone and luteinizing hormone after menopause. Clin Endocrinol 1986;40:783–789.

    External Resources

  6. Mason M, Hernandez-Valencia M, Zarate A, Fonseca ME, Ochoa R: Molecular forms proportion of gonadotrophins is altered in patients with polycystic ovaries syndrome. Ginecol Obstet Mex 1997;65:382–386.
  7. Ulloa-Aguirre, Timossi C, Damian-Matsumura P, Dias JA: Role of glycosylation in function of follicle-stimulating hormone. Endocrine 1999;11:205–215.
  8. Helton TE, Magner JA: Sialytransferase messenger ribonucleic acid increases in thyrotrophs of hypothyroid mice: an in situ hybridization study. Endocrinology 1994;134:2347–2353.
  9. Papandreou M, Sergi I, Medri G, Labbe-Jullie C, Braun JM, Canonne C, Ronin C: Differential effect of glycosylation on the expression of antigenic and bioactive domains in human thyrotropin. Mol Cell Endocrinol 1991;78:137–150.
  10. Sairam MR: Role of carbohydrates in glycoprotein hormone signals transduction. FASEB J 1989;3:1915–1920.
  11. Ulloa-Aguirre A, Midgley AR, Beitins IZ, Padmanabhan V: Follicle-stimulating isohormones: characterization and physiological relevance. Endocrinol Rev 1995;16:765–787.
  12. Stanton PG, Burgon PG, Hearn MTW, Robertson DM: Structural and functional characterisation of FSH and LH isoforms. Mol Cell Endocrinol 1996;125:133–141.
  13. Baenziper JU, Green ED: Pituitary glycoprotein hormone oligosacharides: structure, synthesis and function of the asparagines-linked oligosaccharides on lutropin, follitropin and thyrotropin. Biochim Biophys Acta 1988;947:287–306.
  14. Bousfield GR, Butnev VY, Gotschall RR: Structural features of mammalian gonadotropins. Mol Cell Endocrinol 1996;125:3–19.
  15. Hernandez-Valencia M, Fonseca ME, Ochoa R, Zarate A: Metabolic effects in the menopause from synthetic steroid (tibolone) with characteristic estrogenic action. Ginecol Obstet Mex 1997;65:145–147.
  16. Papandreou MJ, Asteria C, Pettersson K, Ronin C, Beck-Peccoz P: Concanavalin A affinity chromatography of human serum gonadotrophins: evidence for changes of carbohydrate structure in different clinical conditions. J Clin Endocrinol Metab 1993;76:1008–1013.
  17. Creus S, Chaia Z, Pellizzari EH, Cigorraga SB, Ulloa-Aguirre A, Campo S: Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity. Mol Cell Endocrinol 2001;174:41–49.
  18. Creus S, Pellizzari E, Cigorraga SB, Campo S: FSH isoforms: bio and immuno-activities in post-menopausal and normal menstruating women. Clin Endocrinol 1996;44:181–189.
  19. Savastano S, Tommaselli AP, Valentino R, Luciano A, Gigante M, Randazzo G, Contaldo F, Scalfi L, Lombardi G: Changes in the glycosylation pattern of circulating gonadotrophins alter acute administration of gonadotrophin-releasing hormona in patients with anorexia nervosa. Eur J Endocrinol 1998;138:76–81.
  20. Padmanabhan V, Sairam MR, Hassing JM, Brown MB, Riding JW, Beitins IZ: Follicle-stimulating hormone signal transduction: role of carbohydrate in aromatase induction in immature rat Sertoli cells. Mol Cell Endocrinol 1991;79:119–128.
  21. Robertson DM, Foulds LM, Fry RCM, Cummings JT, Clarke I: Circulating half-lives of follicle-stimulating hormone and luteinizing hormone in pituitary extracts and isoform fractions of ovariectomized and intact ewes. Endocrinology 1991;129:1805–1813.
  22. Ziecik AJ, Derecka-Reszka K, Rzucidlo SJ: Extragonadal gonadotropin receptors, their distribution and function. J Phylsiol Pharmacol 1992;43:33–49.

    External Resources

  23. Ulloa-Aguirre A, Stanislaus D, Aurora V, et al: The third intracellular loop of the rat gonadotrophin-releasing hormone (GnRH) receptor couples the receptor to Gs- and Gp/11-mediated signal transduction pathways: evidence from loop fragment transfection in GGH3 cells. Endocrinology 1998;139:2472–2478.
  24. Davis D, Liu X, Segaloff DL: Identification of the sites of N-linked glycosylation on the follicle-stimulating hormone (FSH) receptor and assessment of their role in FSH receptor function. Mol Endocrinol 1995;9:159–170.
  25. Hartree SA, Renwick GCA: Molecular structures of glycoprotein hormones and functions of their carbohydrate components. Biochem J 1992;287:665–679.
  26. Peixin Y, Kriatchko A, Shyamal KR: Expression of ER-α and ER-β in the hamster ovary: Differential regulation by gonadotrophins and ovarian steroid hormones. Endocrinology 2002;143:2385–2398.
  27. Timossi C, Barrios-de-Tomasi J, Zambrano E, Ulloa-Aguirre A: A naturally occurring basically charged human follicle-stimulating hormone (FSH) variant inhibits FSH-induced androgen aromatization and tissue-type plasminogen activator enzyme activity in vitro. Neuroendocrinology 1998;67:153–163.
  28. Smith PL, Baenzinger JU: A pituitary N-acetylgalactosamine transferase that specifically recognizes glycoprotein hormones. Science 1988;242:930–933.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50